Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MESO vs MNKD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MNKD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

MNKD Overall Winner 6-Pillar Tally: MESO 2 – 4 MNKD Matrix Metrics: MESO 2 – 8 MNKD

As of Nov 16, 2026, Mannkind Corporation (MNKD) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas MNKD carries 36.1/100 (SELL) at $3.91 (26.2x Forward P/E, -3.4% operating margin).

  • Growth vs. Quality Trade-Off: MNKD earns the overall head-to-head edge with a stronger Unified Composite Score (36.1/100 SELL vs. MESO 34.6/100 SELL) and 1.29β · 48% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although MNKD compares more favorably head-to-head, both MESO (34.6/100 SELL) and MNKD (36.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile MNKD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 59.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MESO vs MNKD
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
34.6 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $13.64 · SMA50: $14.22
MNKD NASDAQ Head-to-Head Winner
Mannkind Corporation
Pharmaceutical Preparations
$3.91
-5.33% 1D
Market Cap $1.3B
TTM Revenue $413M
Forward P/E 26.2x
Beta / 30D Vol 1.29β · 48% Vol
Unified Composite Score
36.1 / 100 SELL
Tech 50.0 Fund 38.0 Flow 72.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 60
RSI-14: 59.7 · SMA20: $3.67 · SMA50: $3.57

6-Pillar Scorecard Institutional Category Breakdown (MESO 2 – 4 MNKD)

Columns: Metric · MESO · MNKD
1. Valuation Multiples MNKD
Forward P/E N/M 26.2x
Trailing P/E N/M 32.3x
PEG Ratio N/M 4.39x
EV / Revenue 14.1x 3.9x
2. Growth & Scale MESO
Revenue Growth (YoY) +390.7% +24.0%
Earnings Growth (YoY) +0.0% -34.9%
TTM Revenue (USD) $120M $413M
Market Cap $1.7B $1.3B
3. Profitability & Quality MNKD
Gross Margin 80.0% 75.8%
Operating Margin -42.6% -3.4%
Net Profit Margin -47.8% -18.1%
Return on Equity (ROE) -9.9% 0.0%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$45M EBITDA -$78M
Cash Flow Margin -37.1% EBITDA Mgn -19.0%
Net Cash / Leverage $4.38 Book/Sh · -9.9% ROE $289M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MNKD
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 76.8% (37th %ile) 66.9% (7th %ile)
Put/Call OI Skew Thin ADR Chain 0.05x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat MNKD
OpEx & R&D Intensity N/A 79.2% of Rev ($327M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MESO (2) vs MNKD (8)
Institutional Metric MESO MNKD Criterion Row Edge
Market Capitalization
Scale
$1.7B $1.3B Larger Scale MESO
Trailing P/E Ratio
Valuation
N/M 32.3x Lower Multiple MNKD
Forward P/E Ratio
Valuation
N/M 26.2x Lower Multiple MNKD
Revenue Growth (YoY)
Growth
+390.7% +24.0% Higher Growth MESO
Operating Margin (TTM)
Profitability
-42.6% -3.4% Higher Margin MNKD
Net Profit Margin
Profitability
-47.8% -18.1% Higher Margin MNKD
Return on Equity (ROE)
Capital Efficiency
-9.9% 0.0% Higher ROE MNKD
52-Week Range Position
Momentum
6% ($12–$22) 39% ($2–$7) Stronger Trend MNKD
Beta / 30D Volatility
Risk Regime
1.18β · 78% Vol 1.29β · 48% Vol Lower Realized Risk MNKD
Unified Institutional Score
Composite Signal
34.6 / 100 (SELL) 36.1 / 100 (SELL) Higher Composite MNKD
Trailing 12M Revenue (USD)
Operating Scale
$120M $413M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
80.0% 75.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.1x EV/Rev 4.39x PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) -$78M ($289M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MNKD +34.72 pp
MESO: -6.1% · MNKD: +28.62%
3M Horizon MNKD +21.26 pp
MESO: -25.19% · MNKD: -3.93%
6M Horizon MNKD +45.59 pp
MESO: -14.82% · MNKD: +30.77%
1Y Horizon MESO +6.46 pp
MESO: -16.42% · MNKD: -22.88%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs MNKD. Trailing 12-month operating profitability (MESO -42.6% vs MNKD -3.4%) and valuation multiples (MESO N/M vs MNKD 26.2x Forward P/E) are benchmarked directly in Pillar 4 below.

MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M
MNKD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$413M
Gross Margin75.8%
Op. Margin-3.4%
ROE / Fwd P/E0.0% · 26.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MNKD CONSOLIDATION
95d in phase · OBV ACCUMULATION
Current IV 66.9%
IV Percentile 7th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MNKD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MNKD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -3.4% operating margin.
OpEx & R&D Reinvestment 79.2% of Rev ($327M)
90D Engineering Disclosures 0 Published

Investor FAQ MESO vs MNKD Key Questions & Quantitative Answers

As of Nov 16, 2026, Mannkind Corporation (MNKD) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas MNKD carries 36.1/100 (SELL) at $3.91 (26.2x Forward P/E, -3.4% operating margin). Growth vs. Quality Trade-Off: MNKD earns the overall head-to-head edge with a stronger Unified Composite Score (36.1/100 SELL vs. MESO 34.6/100 SELL) and 1.29β · 48% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although MNKD compares more favorably head-to-head, both MESO (34.6/100 SELL) and MNKD (36.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile MNKD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 59.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: MESO posts +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin), compared with MNKD at +24.0% YoY revenue growth and -34.9% YoY earnings growth on $413M TTM revenue (75.8% gross margin, -3.4% operating margin). On trailing 12-month operating scale, MESO generates $120M in USD-normalized revenue versus $413M for MNKD. In operating R&D and SG&A reinvestment, MESO deploys N/A (0 90-day corporate R&D disclosures) versus 79.2% of Rev ($327M) (0 disclosures) for MNKD.

MNKD screens cheaper on headline valuation multiples. MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin), whereas MNKD trades at 26.2x Forward P/E, 32.3x Trailing P/E, 4.39x PEG, and 3.9x EV/Revenue (-19.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MESO (-9.9% ROE) versus MNKD (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk). By comparison, MNKD carries 66.9% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.